Leuven, Belgium, September 12th, 2023 – Augustine Therapeutics, a biotech company developing innovative therapies for neuromuscular and neurodegenerative disorders, announced today the expansion of its leadership team with Marie Trad, MD as Chief Medical Officer, Jonathan van Eyll, PhD as Head of Pharmacology and Cédric Szyndralewiez, MSc as Head of Non-Clinical and Early Development. The company is also opening its state-of-the-art R&D laboratories and offices in the new Arenberg Accelerator building located in Leuven. Growing the R&D team and internal capacity will further accelerate the development of Augustine’s HDAC6-focused programs towards the clinic for the treatment of Charcot-Marie-Tooth disease (CMT), chemotherapy-induced peripheral neuropathy (CIPN), as well as CNS diseases such as amyotrophic lateral sclerosis (ALS).